Key result
Peak alpha frequency measured with electroencephalography did not consistently predict interindividual or intraindividual sensitivity to brief experimental pain across two recording sessions.
Why the study?
Peak alpha frequency predicts sensitivity to longer-lasting pain, but whether this relationship generalizes across pain types remains unclear.
Does peak alpha frequency predict sensitivity to brief experimental pain in healthy participants?
Observational (n=159)
No
Does peak alpha frequency predict sensitivity to brief experimental pain in healthy participants?
Effect estimate: R = -0.15
p-value: p=BF10 = 1.04
Peak alpha frequency does not consistently predict sensitivity to brief experimental pain, suggesting its role as a pain biomarker may not generalize to all pain types.
Caution against using PAF to predict brief experimental pain sensitivity; leaves open its biomarker potential in other pain contexts.
Pain perception varies considerably between and within individuals. How the brain determines these variations has yet to be fully understood. The peak frequency of alpha oscillations has recently been shown to predict an individual's sensitivity to longer-lasting experimental and clinical pain. Peak alpha frequency (PAF) is, thus, discussed as a potential biomarker and novel target for neuromodulatory treatments of pain. Here, we scrutinized the generalizability of the relation between PAF and pain. We applied brief painful laser stimuli to 159 healthy participants and related interindividual and intraindividual variations of pain perception to PAF measured with electroencephalography. Comprehensive multiverse analyses replicated across 2 sessions did not provide consistent evidence for a predictive role of PAF for brief experimental pain. This indicates that the relationship between PAF and pain does not generalize to all types of pain and calls for a systematic exploration of the relationship between PAF, pain perception, and other neuropsychiatric symptoms. Such explorations help to understand the prospects and limits of biomarkers and might guide future research on biomarkers of pain and neuropsychiatric disorders.
No takes yet. Share an insight, caveat, or question.
May et al. (2025) conducted an observational in Healthy participants (pain sensitivity) (n=159). Peak alpha frequency (PAF) was evaluated on Correlation between S1 resting-state peak alpha frequency and interindividual variations of pain perception (R = -0.15, p=BF10 = 1.04). Peak alpha frequency measured with electroencephalography did not consistently predict interindividual or intraindividual sensitivity to brief experimental pain across two recording sessions.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: